학술논문
P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES
Document Type
article
Author
Source
HemaSphere, Vol 7, Iss S2, Pp 41-42 (2023)
Subject
Language
English
ISSN
2572-9241